Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004463 | 0.75 | ACKR3 (0.36) | ACKR3GPR119USP30TP53ENPP2 | |
| SCHEMBL6004471 | 0.73 | NR1H2 (0.37) | ACKR3 | |
| SCHEMBL6004209 | 0.68 | ACKR3 (0.40) | ACKR3USP30TP53ENPP2JAK2 | |
| SCHEMBL4791025 | 0.67 | NR1H2 (0.46) | BACE1BACE2USP30ENPP2 | |
| SCHEMBL4763333 | 0.65 | ACKR3 (0.49) | ACKR3ENPP2 | |
| SCHEMBL4828575 | 0.65 | MAPK14 (0.48) | ACKR3 | |
| SCHEMBL6003976 | 0.64 | ACKR3 (0.39) | ACKR3TRPV3GPR119USP30TP53 | |
| SCHEMBL28479279 | 0.63 | GPR119 (0.43) | GPR119USP30TP53 | |
| SCHEMBL15858050 | 0.62 | GPR119 (0.48) | GPR119 | |
| SCHEMBL21340083 | 0.62 | HDAC1 (0.46) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | ACKR3 262/4885BACE1 1540/4885BACE2 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.